Abstract
Patients with squamous cell carcinoma of the head and neck (HNSCC) are usually treated by a multimodal approach with surgery and/or radiochemotherapy as the mainstay of localregional treatment in cases with advanced disease. Both chemotherapy and radiation therapy have the disadvantage of causing severe side effects, while the clinical outcome of patients diagnosed with HNSCC has remained essentially unchanged over the last decade. The potential of immunotherapy is still largely unexplored. Here the authors review the current status of the art and discuss the future challenges in HNSCC treatment and prevention.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 22-42 |
| Number of pages | 21 |
| Journal | International Reviews of Immunology |
| Volume | 31 |
| Issue number | 1 |
| DOIs | |
| State | Published - Feb 2012 |
Fingerprint
Keywords
- Cancer vaccines
- CRT
- EGFR
- HNSCC
- HPV
ASJC Scopus subject areas
- Immunology
- Immunology and Allergy
Cite this
Immunological treatment options for locoregionally advanced head and neck squamous cell carcinoma. / Schutt, Christopher; Bumm, Klaus; Mirandola, Leonardo; Bernardini, Giovanni; Cunha, Nicholas D.; Tijani, Lukman; Nguyen, Diane; Cordero, Joehassin; Jenkins, Marjorie R.; Cobos, Everardo; Kast, W. Martin; Chiriva-Internati, Maurizio.
In: International Reviews of Immunology, Vol. 31, No. 1, 02.2012, p. 22-42.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Immunological treatment options for locoregionally advanced head and neck squamous cell carcinoma
AU - Schutt, Christopher
AU - Bumm, Klaus
AU - Mirandola, Leonardo
AU - Bernardini, Giovanni
AU - Cunha, Nicholas D.
AU - Tijani, Lukman
AU - Nguyen, Diane
AU - Cordero, Joehassin
AU - Jenkins, Marjorie R.
AU - Cobos, Everardo
AU - Kast, W. Martin
AU - Chiriva-Internati, Maurizio
PY - 2012/2
Y1 - 2012/2
N2 - Patients with squamous cell carcinoma of the head and neck (HNSCC) are usually treated by a multimodal approach with surgery and/or radiochemotherapy as the mainstay of localregional treatment in cases with advanced disease. Both chemotherapy and radiation therapy have the disadvantage of causing severe side effects, while the clinical outcome of patients diagnosed with HNSCC has remained essentially unchanged over the last decade. The potential of immunotherapy is still largely unexplored. Here the authors review the current status of the art and discuss the future challenges in HNSCC treatment and prevention.
AB - Patients with squamous cell carcinoma of the head and neck (HNSCC) are usually treated by a multimodal approach with surgery and/or radiochemotherapy as the mainstay of localregional treatment in cases with advanced disease. Both chemotherapy and radiation therapy have the disadvantage of causing severe side effects, while the clinical outcome of patients diagnosed with HNSCC has remained essentially unchanged over the last decade. The potential of immunotherapy is still largely unexplored. Here the authors review the current status of the art and discuss the future challenges in HNSCC treatment and prevention.
KW - Cancer vaccines
KW - CRT
KW - EGFR
KW - HNSCC
KW - HPV
UR - http://www.scopus.com/inward/record.url?scp=84856082393&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84856082393&partnerID=8YFLogxK
U2 - 10.3109/08830185.2011.637253
DO - 10.3109/08830185.2011.637253
M3 - Article
VL - 31
SP - 22
EP - 42
JO - International Reviews of Immunology
JF - International Reviews of Immunology
SN - 0883-0185
IS - 1
ER -